Skip to main content

Three case reports of post immunization and post viral Bullous Pemphigoid: looking for the right trigger



Bullous pemphigoid (BP) is a blistering skin disorder infrequent in infancy and rarely reported in medical literature.

Case Presentation

Here we describe three cases of BP which were referred to our department in the last 15 years. Two of them developed an eruption of bullous lesions just a few days after vaccination for diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and Haemophilus influenzae B. The third patient developed the same blistering lesions shortly after herpetic stomatitis. In all three cases, clinical diagnosis was confirmed by histological examination which showed subepidermal bullae with a dermal inflammatory infiltrate, and direct immunofluorescence of perilesional skin showed linear IgG and C3 deposits along the basement membrane zone. Immunoblot assay was positive for BP antigen 180. Treatment with oral prednisone was instituted and the lesions resolved in two out of three patients; the third one was treated with an immunosuppressive agent (tacrolimus) and corticosteroid and subsequently with intravenous immunoglobulin and plasmapheresis, due to an underlying complex autoimmune disease.


Although the mechanism of induction of BP is still unclear, the close relationship between trigger events (immunization or viral infection) and onset of the disease arises a possible association.

Peer Review reports


Bullous pemphigoid (BP) is an autoimmune blistering skin disorder associated with presence of tissue-bound and circulating IgG autoantibodies directed against hemidesmosomal proteins, called BP antigen 180 and BP antigen 230 [1]. Bullous pemphigoid usually affects the elderly and is rare in childhood and infancy. BP is diagnosed on the basis of clinical, histologic and immunologic findings [2, 3]. Among possible trigger factors of BP, immunization and viral infections are mentioned in literature. Some cases of BP have been reported soon after vaccine administration, although the immunological mechanism underneath is still unclear [46].

The clinical presentation of BP amongst children differs from that seen in adults, notably in terms of acral involvement with predominance of palmoplantar lesions, sparing the mucosa and genital area, in children aged less than 1 year. Unlike in adults, childhood BP has usually a good prognosis and resolves quite rapidly after initiation of treatment [7].

Although a clear trigger is not well established for BP, especially in infancy, a combination of multiple factors can be postulated. We present here 3 cases of children younger than 2 years who were referred to our Hospital in the last 15 years after developing BP related in time with a previous episode of vaccination or viral infection.

Case Presentation

A previously healthy 3-month-old boy was referred to our Hospital with a 15-day history of a blistering eruption on his hands and feet. He received a first dose of combined vaccination against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and Haemophilus influenzae B 2 days before the onset of the bullous rash. He had been previously treated at home with topical gentamicin and oral co-amoxiclavulante, without resolution of the skin eruption. There was no relevant family history for autoimmune or blistering disorders and no risk factors during pregnancy or delivery had been identified. Infant was breast-fed and growing normally. Clinically he presented with blistering lesions with a prevailing acral distribution: large vesicles and tense bullae with surrounding erythema were seen on the palms and soles, whereas widespread smaller blisters on erythematous skin could be noticed on the trunk and abdomen (Figs. 1 and 2). Mucous membranes were not involved and other systems’ examination was unremarkable. Observations were within normal limits and the patient was afebrile. Results of laboratory investigations showed that the patient had a mild eosinophilia (1.47 × 109/L, 12% of WBC count); inflammatory markers and complement components were normal. Bacteriology analysis of the fluid inside blisters revealed no infections and blood virological tests were negative. A first biopsy for histologic study was taken from a recent vesicular lesion and showed subepidermal blister with a mixed superficial perivascular inflammatory infiltrate with abundant eosinophils. A second biopsy for direct immunofluorescence (DIF) was taken from uninvolved perilesional skin: the results of DIF showed linear deposition of immunoglobulin G (IgG, faint deposits) and complement component 3 (C3, intense deposits) along the basement membrane zone leading to the diagnosis of bullous pemphigoid (Fig. 3). The immunoblot assay was positive for BP antigen 180. Oral steroids have been started with prednisone at 1.5 mg/kg/day for ten days. Once the development of blisters was stopped and erythema had subsided, a careful tapering of prednisone was started, following an alternate day scheme. Considering the severity of the disease and the young age of infants, we started with a higher dose than suggested in guidelines [2]. For the whole duration of steroid treatment, the patient was subjected to a strict follow-up: therapy was well tolerated, with no adverse effects, as hypertension, weight gain, hyperglycemia or other blood test alterations. Prednisone was carefully tapered off over a 2-month period with no evidence of disease relapse and currently the patient is still in remission. Resumption of the vaccination schedule did not induce any recurrence of the disease.

Fig. 1
figure 1

Patient 1: widespread small blisters on erythematous skin of the trunk and abdomen

Fig. 2
figure 2

Patient 1: large vesicles and tense bullae with surrounding erythema located in feet, with palm and sole involvement

Fig. 3
figure 3

Patient 1: direct immunofluorescence showing linear deposition of IgG along the basement membrane zone

A 17-month-old girl with a history of eczema and autoimmune enteropathy developed a blistering eruption on her hands and feet a few days after the second dose of hexavalent vaccination. Considering the autoimmune disorder affecting her gut, on the recommendation of gastroenterologists, she was treated with an immunosuppressive agent (tacrolimus) and corticosteroid; during a suspension of therapy for remission of gastrointestinal symptoms, she received the first dose of hexavalent vaccination at the age of 15 months with appearance of a single blister on the back of one hand 5 days later. At the age of 17 months 7 days after the second dose of vaccination, she developed a bullous rash on the limbs which subsequently spread to the whole body. Two punch biopsies were taken, one for the histologic examination and the other for DIF, and they led to the diagnosis of bullous pemphigoid. The girl was treated with oral prednisone 1 mg/kg/day; as the lesions did not improve the dose was increased to 2 mg/kg/day but still without benefit. Subsequently she received intravenous Ig and finally plasmapheresis (5 sessions) with full recovery within 6 months. The patient developed over the years an IPEX-like syndrome caused by deficiency of CD25 (IL2-RA), characterized by immunodeficiency and autoimmunity, which was genetically confirmed. She recently underwent a bone marrow transplant with success.

A 2-month-old girl with unremarkable family history for bullous diseases, developed an eruption of bullous lesions, on an erythematous base, confluent, located in both hands and feet, with palm and sole involvement, together with multiple ovaloid erythematous plaques, some with vesicles, on the abdomen. Ten days before she had been diagnosed with acute gingivostomatitis subsequently confirmed by PCR detection of HSV-1 DNA as herpetic stomatitis. At the beginning, to avoid bullous impetigo, the infant was managed with intravenous co-amoxiclavulanate. IgM antibody titer against HSV-1 was positive and suggestive of recent infection. A skin biopsy subsequently confirmed BP, showing sub-epidermal blisters. A second biopsy for direct immunofluorescence DIF showed linear deposits of IgG and C3 at the epidermal BMZ, confirming the diagnosis of bullous pemphigoid. Immunoblot assay was positive for BP antigen 180. The infant was managed with oral prednisone 1 mg/kg/day with rapid improvement, and she became free of blisters after 3 weeks of treatment. Follow-up to 6 months was good.

All parents of the three reported cases provided written informed consent to the inclusion of data concerning their infants in the manuscript in compliance with the Helsinki Declaration.


The reported cases are presentations of bullous pemphigoid, the most prevalent autoimmune blistering skin disease, presenting with tense blisters on erythematous skin, predominantly affecting elderly people and unusual in infancy. Bullous pemphigoid is usually a self-limiting disease with a clinical course that may last from months to years in adults. In childhood and infancy BP usually responds well to conventional treatments, with a good prognosis [8].

The etiopathogenesis of bullous pemphigoid is complex and during recent years much has been postulated regarding the trigger factors related to the development of this condition, as immunizations and viral infections [911]. None of our patients had a suggestive family history for blistering skin disease and specifically their mothers did not develop gestational pemphigoid during pregnancy.

Here we report the case of two infants who developed an eruption of bullous lesions just a few days after vaccination against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and Haemophilus influenzae B, while the third patient after a viral infection by HSV-1. The latency period ranged between 2 and 10 days. A too short interval from immunization to onset of skin lesions could be considered an argument against the existence of a true relationship: since IgG production begins 10–14 days post-immunization, a 2–3 day latency period would generally be considered too short a time-frame for autoimmune manifestations characterized by IgG deposition to develop. Some authors anyway have suggested that certain vaccines may unmask subclinical BP by inducing a nonspecific immune reactivation in genetically predisposed infants more sensitive to the stimulus [8]. Others hypothesized that intrauterine transmitted maternal IgG antibodies might play a role [4] but a vertical transference of antibodies seems unlikely since in all the cases of PB reported in the literature where tests on mother’s serum were performed, circulating anti-BMZ antibodies were not found [11]. Moreover, according to recent studies, the trauma caused by the vaccine injection may led to Th17 cell activation with increased of IL-17 which is able to release pro-inflammatory cytokines and proteolytic enzymes, which may result in blister formation [12]. Finally, CD25 deficiency may be related to BP, since the lack of CD25+ cells has been observed in bullous pemphigoid lesions [13].

In literature some tens of cases of childhood BP have been reported, of which about 20 have been related to vaccine administration, but only a few occurred in infants younger than 6 months of age [6, 10, 14]. Anyway, the association of BP and vaccination could be entirely coincidental, given that vaccination in infants is a usual and daily practice in developed countries while cases of BP reported in infants are really limited. The high rate of vaccinations in the first year of life in contrast with the low number of reported cases of BP after vaccination makes it difficult to explain a causal relationship, even if described cases of recurrence after a new dose of vaccination seem to reinforce the hypothesis of a causal association [8].

Although the histopathological and immunological features of infantile BP are indistinguishable from those of childhood BP and adult BP, age-related differences in regional distribution of lesions were demonstrated. A recent study found that lesions are more likely located on the extremities during the first year of life [15]. For this reason, the clinical presentation of infantile BP seems to differ from that of childhood and adult BP, which are characterized by tense blisters predominantly appearing along folds in the skin on the lower abdomen, groin, upper thighs and arms. In our cases there was no correspondence between the location of the vaccine administration and the site of occurrence of the first lesions.

The diagnosis of BP in our three cases has been confirmed with DIF studies on perilesional skin, which showed linear deposits of IgG and/or C3 at the epidermal BMZ [16]. To perform the DIF, frozen sections fixed in acetone at a temperature of 4 °C were incubated with Ig fluorescein isothiocyanate in humid chamber (IgA,IgM,C3 diluite 1/10; IgG 1/20), then rinsed in PBS and covered with anti-fade mounting medium.

Laboratory investigations are nonspecific, while histopathologic analysis shows sub-epidermal blisters. Diagnostic findings for BP are listed in Table 1. In our cases indirect immunofluorescence and detection of circulating autoantibodies against PB antigens were not performed.

Table 1 Diagnostic findings for BP

Regarding differential diagnosis, BP should be differentiated from other subepidermal diseases: most of all DIF is useful in distinguishing BP from epidermolysis bullosa acquisita, mucous membrane pemphigoid and linear IgA disease. Bullous lesions may also be caused by insect bites, burns, cellulitis and contact dermatitis. Viral and bacterial skin infections should be recognized and treated before starting immunosuppressive therapy [7, 16].

Treatment with oral prednisone was instituted and the lesions rapidly resolved in two out of three patients, with suppression of inflammation and blistering typically achieved in a period of a few weeks, after which the dose was gradually reduced; the third one was treated with an immunosuppressive agent (Tacrolimus) and corticosteroid and subsequently with intravenous immunoglobulin and plasmapheresis, due to a complex underlying autoimmune disease [7].

According to a Cochrane review by Kirtschig et al. oral corticosteroid drugs are the most common treatment regimens and starting doses of prednisolone of 0.75 mg/kg/day or less seem to be adequate to control disease and reduce the incidence and severity of adverse reactions [17].

Other treatments with reported benefit are potent topical steroids, azathioprine, mycophenolate mofetil, dapsone, methotrexate, cyclosporin, cyclophosphamide, plasma exchange, as well as erythromycin and tetracycline as monotherapy or with nicotinamide [7, 17]. There is a small number of case reports for the use of intravenous immunoglobulin (IVIg) [18]. Reports have also described successful therapy of BP patients with rituximab in treatment-refractory forms [19].

Since up to 40% of patients with BP on systemic corticosteroids develop severe infectious complications resulting in hospitalization or death [20] we administered a broad-spectrum antibiotic therapy to our 3 patients.


In this article we reported two infants who developed an eruption of bullous lesions just a few days after vaccination against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and Haemophilus influenzae B, while the third patient showed the same lesions after a viral infection by HSV-1. Although the mechanism of induction is unclear, the close relationship between trigger events and onset of the disease suggests that there may be an association. Treatment with oral prednisone was effective in achieving disease control in two out of three patients; the third one was treated with a combination of systemic corticosteroids and Tacrolimus and subsequently with intravenous immunoglobulin and plasmapheresis, due to a complex underlying autoimmune disease. BP is an uncommon autoimmune skin disorder in infancy, although recently some cases have been reported after vaccinations or viral infections [21, 22]. In most cases it shows prominent palmoplantar involvement and responds well to systemic steroid therapy, even if recognizing it promptly is important to establish appropriate treatment and prevent infectious complications which may be common and severe. More research will in fact be necessary to refine and further elaborate our knowledge on right trigger events of BP in infants.



Basement membrane zone


Bullous pemphigoid


Complement component 3


Direct immunofluorescence


Herpes simplex virus type 1


Immunoglobulin G


Immunoglobulin M


Polymerase chain reaction


  1. Kuenzli S, Grimaître M, Krischer J, Saurat J-H, Calza A-M, Borradori L. Childhood bullous pemphigoid: report of a case with life-threatening course during homeopathy treatment. Pediatr Dermatol. 2004;21(2):160–3.

    Article  PubMed  Google Scholar 

  2. Fuertes De Vega I, Iranzo-Fernández P, Mascaró-Galy JM. Bullous pemphigoid: clinical practice guidelines. Actas Dermosifiliogr. 2014;105:328–46. doi:10.1016/

    Article  CAS  PubMed  Google Scholar 

  3. Otten JV, Hashimoto T, Hertl M, Payne AS, Sitaru C. Molecular diagnosis in autoimmune skin blistering conditions. Curr Mol Med. 2014;14:69–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Hafiji J, Bhogal B, Rytina E, Burrows NP. Bullous pemphigoid in infancy developing after the first vaccination. Clin Exp Dermatol. 2010;35(8):940–1.

    Article  CAS  PubMed  Google Scholar 

  5. Gurel MS, Savas S, Bilgin F, Erdil D, Leblebici C, Sarikaya E. Zosteriform pemphigoid after zoster: Wolf’s isotopic response. Int Wound J. 2016;13(1):141–2.

    Article  PubMed  Google Scholar 

  6. De la Fuente S, Hernández-Martín Á, de Lucas R, González-Enseñat MA, Vicente A, Colmenero I, et al. Postvaccination bullous pemphigoid in infancy: report of three new cases and literature review. Pediatr Dermatol. 2013;30(6):741–4.

    Article  PubMed  Google Scholar 

  7. Venning VA, Taghipour K, Mohd Mustapa MF, Highet AS, Kirtschig G. British Association of Dermatologists’ guidelines for the management of bullous pemphigoid 2012. Br J Dermatol. 2012;167(6):1200–14.

    Article  CAS  PubMed  Google Scholar 

  8. Fisler RE, Saeb M, Liang MG, Howard RM, McKee PH. Childhood bullous pemphigoid: a clinicopathologic study and review of the literature. Am J Dermatopathol. 2003;25(3):183–9.

    Article  PubMed  Google Scholar 

  9. Erbagci Z. Childhood bullous pemphigoid following hepatitis B immunization. J Dermatol. 2002;29(12):781–5.

    Article  PubMed  Google Scholar 

  10. Ister M, Pouessel G, Ythier H, Catteau B, Carpentier O. Postvaccinal, corticosteroid-resistant bullous pemphigoid in infancy: treatment with intravenous immunoglobulin. Pediatr Dermatol. 2014;1(4):e94–5.

    Article  Google Scholar 

  11. Neri I, Greco A, Bassi A, Orgaz-Molina J, Balestri R, Oranges T, et al. Bullous pemphigoid in infant post vaccination: Myth or reality? Int J Immunopathol Pharmacol. 2015;29(2):295–9.

    Article  PubMed  Google Scholar 

  12. Lo Schiavo A, Ruocco E, Brancaccio G, et al. Bullous pemphigoid: Etiology, pathogenesis, and inducing factors: Facts and controversies. Clin Dermatol. 2013;31:391–9.

    Article  PubMed  Google Scholar 

  13. Antiga E, Quaglino P, Volpi W, Pierini I, Del Bianco E, Bianchi B, Novelli M, Savoia P, Bernengo MG, Fabbri P, Caproni M. Regulatory T cells in skin lesions and blood of patients with bullous pemphigoid. J Eur Acad Dermatol Venereol. 2014;28:222–30. doi:10.1111/jdv.12091.

    Article  CAS  PubMed  Google Scholar 

  14. Schwieger-Briel A, Moellmann C, Mattulat B, Schauer F, Kiritsi D, Schmidt E, et al. Bullous pemphigoid in infants: characteristics, diagnosis and treatment. Orphanet J Rare Dis. 2014;9(1):185.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Waisbourd-Zinman O, Ben-Amitai D, Cohen AD, Feinmesser M, Mimouni D, Adir-Shani A, et al. Bullous pemphigoid in infancy: Clinical and epidemiologic characteristics. J Am Acad Dermatol. 2008;58(1):41–8.

    Article  PubMed  Google Scholar 

  16. Kasperkiewicz M, Zillikens D, Schmidt E. Pemphigoid diseases: pathogenesis, diagnosis, and treatment. Autoimmunity. 2012;45(1):55–70.

    Article  CAS  PubMed  Google Scholar 

  17. Kirtschig G, Middleton P, Bennett C, Murrell DF, Wojnarowska F, Khumalo NP. Interventions for bullous pemphigoid. Cochrane Database Syst Rev. 2010. doi:10.1002/14651858.CD002292.pub3.

    PubMed  Google Scholar 

  18. Sugawara N, Nagai Y, Matsushima Y, Aoyama K, Ishikawa O. Infantile bullous pemphigoid treated with intravenous immunoglobulin therapy. J Am Acad Dermatol. 2007;57(6):1084–9.

    Article  PubMed  Google Scholar 

  19. Kasperkiewicz M, Shimanovich I, Ludwig RJ, Rose C, Zillikens D, Schmidt E. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol. 2011;65(3):552–8.

    Article  CAS  PubMed  Google Scholar 

  20. Phoon YW, Fook-Chong SMC, Koh HY, Thirumoorthy T, Pang SM, Lee HY. Infectious complications in bullous pemphigoid: An analysis of risk factors. J Am Acad Dermatol. 2015;72(5):834–9.

    Article  PubMed  Google Scholar 

  21. Iyengar S, Awasthi S, Fazel N, Okman J, Kamangar F, Sharon VR. Acral bullae in an infant. Arch Dis Child. 2016. doi:10.1136/archdischild-2016-310535.

    PubMed  Google Scholar 

  22. Taquin H, Chiaverini C, Lacour JP. Spectrum of Clinical Responses to Therapies in Infantile Bullous Pemphigoid. Pediatr Dermatol. 2016;33(2):e77–81.

    Article  PubMed  Google Scholar 

Download references


We are grateful to parents of the three reported patients who made contributions to acquisition of data described in the manuscript.



Availability of data and materials

Raw data from the study are available upon request from the corresponding author.

Authors’ contributions

L.B. conceptualized and designed the study, drafted the initial manuscript and references, revised and approved the final manuscript as submitted. P.C. carried out the initial analyses, drafted the initial manuscript, reviewed and revised the manuscript, and approved the final manuscript as submitted. L.B. performed the analyses with direct immunofluorescence, reviewed and revised the manuscript, and approved the final manuscript as submitted. S.M. critically reviewed the manuscript, edited the article and approved the final manuscript as submitted. F.S. designed and coordinated the data collection, wrote the initial manuscript, critically reviewed the manuscript, and approved the final manuscript as submitted.

Competing interests

The authors have no conflicts of interest relevant to this article to disclose. The authors have no financial relationships relevant to this article to disclose.

Consent to publication

Written Informed consent for the publication of their details and clinical images was obtained from the parents of the patients.

Ethics approval and consent to participate

The study was approved by the local ethics committee (Comitato Interaziendale AA.SS.OO. O.I.R.M./S. Anna - Ordine Mauriziano di Torino prot. N 632/2015) before the start, and written informed consent was obtained from parents of infants before inclusion in the manuscript.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Francesco Savino.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Baroero, L., Coppo, P., Bertolino, L. et al. Three case reports of post immunization and post viral Bullous Pemphigoid: looking for the right trigger. BMC Pediatr 17, 60 (2017).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: